Castle Creek Arbitrage’s Ibere Pharmaceuticals IBER Stock Holding History

Castle Creek Arbitrage’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-253,446	Closed	-$2.56M	–	567
2022 Q4	$2.56M	Hold	253,446	–	–	0.23%	125
2022 Q3	$2.51M	Hold	253,446	–	–	0.14%	204
2022 Q2	$2.49M	Hold	253,446	–	–	0.14%	207
2022 Q1	$2.48M	Hold	253,446	–	–	0.13%	215
2021 Q4	$2.46M	Hold	253,446	–	–	0.12%	219
2021 Q3	$2.46M	Buy	+253,446	New	+$2.45M	0.14%	180

Castle Creek Arbitrage's IBER Position: Q1 2023 in Review

Castle Creek Arbitrage sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 253,446 shares — an estimated $2.56M sold.

Castle Creek Arbitrage first reported a position in IBER in Q3 2021 and held it in 6 quarters. The position peaked at $2.56M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Castle Creek Arbitrage reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Castle Creek Arbitrage sold 253,446 Ibere Pharmaceuticals shares in Q1 2023, an estimated $2.56M.
Castle Creek Arbitrage first reported a position in Ibere Pharmaceuticals in Q3 2021 and held it in 6 quarters.
Castle Creek Arbitrage's Ibere Pharmaceuticals position peaked at $2.56M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Castle Creek Arbitrage's 13F filing for Q1 2023, filed 15 May 2023.